The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yongfeng, Xu, Jinming, Xu, Jiawei, Wang, Yiqing, Wang, Luming, Lv, Wang, Hu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146978/
https://www.ncbi.nlm.nih.gov/pubmed/32308981
http://dx.doi.org/10.1186/s40364-020-00188-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146978/
https://www.ncbi.nlm.nih.gov/pubmed/32308981
http://dx.doi.org/10.1186/s40364-020-00188-2

Ejemplares similares